Craft
  • Home
  •  / PTC Therapeutics
PTC Therapeutics

PTC Therapeutics

Revenue

$538.6 M

FY, 2021

Market Capitalization

$3.7 B

2022-09-20

PTC Therapeutics Summary

Company summary

Overview
PTC Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of orally-administered, small molecule therapeutics that focus on post-transcriptional control processes. The Company's lead product, Translarna, is used for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients with age of over five years and older. Its programs include Translarna for nonsense mutation cystic fibrosis, Translarna for mucopolysaccharidosis type I caused by nonsense mutation, Translarna for nonsense mutation aniridia, and Translarna for nonsense mutation Dravet syndrome/CDKL5, Spinal muscular atrophy in collaboration with Spinal Muscular Atrophy Foundation.
Type
Public
Founded
1998
HQ
South Plainfield, NJ, US | view all locations
Website
http://www.ptcbio.com/en/
Cybersecurity rating
ESG rating
out of 100 | View all ESG data
Sectors

Key people

  • Stuart Peltz

    Stuart Peltz, CEO

    • Neil Almstead

      Neil Almstead, Executive Vice President, Research, Pharmaceutical Operations & Technology

      • Mark Boulding

        Mark Boulding, Executive Vice President and Chief Legal Officer

        • Mary Harmon

          Mary Harmon, Senior Vice President, Corporate Relations

          LocationsView all

          1 location detected

          • South Plainfield, NJ HQ

            United States

            100 Corporate Ct

          PTC Therapeutics Financials

          Summary financials

          Revenue (Q2, 2022)
          $165.5M
          Net income (Q2, 2022)
          ($152.1M)
          Cash (Q2, 2022)
          $158.2M
          EBIT (Q2, 2022)
          ($92.4M)
          Enterprise value
          $4.0B

          Footer menu